Sarepta to charge $300K for Duchenne drug. ‘We tried to be reasonable,’ CEO says
(By Ed Silverman for STAT) The newly approved1 Sarepta Therapeutics drug for Duchenne muscular dystrophy2 will cost about $300,000 a
Read More
Medicare Advantage Plan Switching: Exception or Norm?
(By Gretchen Jacobson, Tricia Neuman and Anthony Damico for Kaiser Family Foundation) About one in ten Medicare Advantage plan enrollees
Read MoreAs profitable fentanyl industry expands in China, US negotiates to halt the deadly trade
(By Kathleen McLaughlin for STAT) BEIJING — Top American and Chinese enforcement officials are negotiating how to fight the rampant
Read MoreHitch Keeps Many High-Deductible Plans From Covering Chronic Care Up Front
(By Michelle Andrews for Kaiser Health News) As the number of people covered by high-deductible health plans soars, some insurers and
Read MoreMedicare beneficiaries per state for all 50 states & Washington DC
(By Laura Dyrda for Becker’s Hospital Review) How many Medicare beneficiaries does each state have? Continue reading article here…… Notice:
Read MoreIllinois’ Cook County launches program to assist uninsured: 5 things to know
(By Morgan Haefner for Beacker’s Hospital Review) Uninsured individuals in Illinois’ Cook County will receive increased healthcare assistance following the
Read MoreNilotinib: Is it the Cure for Lewy Body Dementia?
Don Carano believes there is a cure for Lewy Body Dementia but medical experts disagree and say more research is
Read MoreFDA approves Sarepta’s controversial drug for Duchenne muscular dystrophy
(By Ed Silverman for STAT) he Food and Drug Administration on Monday approved1 a controversial drug to treat Duchenne muscular
Read MoreFor Some Seniors Without Housing, A Parking Lot Is Home
(By Gloria Hillard for NPR) Marge Giaimo makes her way to a picnic table under the shadow of an oak
Read More